GLP-1 Drugs: Ohio Board of Pharmacy Issues FAQs for Compounders - The National Law Review
Ohio Board of Pharmacy issued FAQs clarifying compounding requirements for GLP-1 drugs, impacting compounders and outsourcing facilities.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Compounding pharmacies (503A and 503B) in Ohio and potentially other states following similar guidance should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; no specific deadline but enforcement likely ongoing.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Ohio Board of Pharmacy published FAQs addressing compounding of GLP-1 drugs, including requirements for patient-specific prescriptions, bulk compounding limits, and labeling.
Who it affects
Compounding pharmacies (503A and 503B) in Ohio and potentially other states following similar guidance
What you must do
Review and update compounding practices to align with Ohio Board of Pharmacy FAQs, ensure compliance with state and federal regulations for GLP-1 compounding.
Deadline
Immediately; no specific deadline but enforcement likely ongoing.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- GLP‑1 Compliance: FDA Targets Telehealth Marketing in 30 New Warning Letters - JD Supra
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines